Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

bayer new zealand limited - gadobutrol 302.36 mg/ml equivalent to 0.5 mmol/ml - solution for injection - 0.5 mmol/ml - active: gadobutrol 302.36 mg/ml equivalent to 0.5 mmol/ml excipient: calcobutrol hydrochloric acid trometamol water for injection

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

bayer new zealand limited - gadobutrol 604.72mg equivalent to 1 mmol/ml - solution for injection - 1 mmol/ml - active: gadobutrol 604.72mg equivalent to 1 mmol/ml excipient: calcobutrol hydrochloric acid trometamol water for injection - gadovist 1.0 is indicated in adults and children of all ages including full-term newborns for: · contrast enhancement in cranial and spinal magnetic resonance imaging (mri). for spinal mri this includes: differentiation of intra- and extramedullary tumours, demonstration of solid tumour areas in known syrinx, determination of intramedullary tumour spread. gadovist 1.0 is especially suited for high dose indications, such as cases where the exclusion or demonstration of additional foci may influence the therapy or patient management, for detection of very small lesions and for visualisation of lesions that do not readily take up contrast media. gadovist 1.0 is also indicated for perfusion studies such as the diagnosis of stroke, the detection of focal cerebral ischaemia and tumour perfusion. · contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system. · contrast enhancement in magnetic resonance angiography (ce mra). · contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement.

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection in pre-filled syringe - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection in pre-filled syringe - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection in pre-filled syringe - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - gadobutrol 604,72 mg/ml - eq. gadobutrol 1 mmol/ml - solution for injection in pre-filled syringe - 1,0 mmol/ml - gadobutrol 604.72 mg/ml - gadobutrol